Upgrade to SI Premium - Free Trial

Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at Citizens on Ph2 Miss for Remlifanserin

September 25, 2026 4:11 AM
Citizens analyst Jason Butler lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $33.00 (from $36.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change